Publications by authors named "Madeleine Karpinski"
Introduction: There is no organized prostate cancer screening in Germany. The aim of this study was to investigate the development of incidence and survival in patients with primary malignant tumors of the prostate in relation to changing recommendations of prostate-specific antigen (PSA) screening in guidelines.
Methods: Age-standardized incidence rates and 5-year relative survival (RS) (period approach) were calculated using data from the cancer registry North Rhine-Westphalia with the subset of the administrative district Münster respectively for the years 1992-2019.
Background: The crude mortality rate and the lifetime mortality risk from prostate cancer in Germany are above international average. However age-standardised mortality and years of life lost per capita from prostate cancer are declining. This study analyses the mortality-related measures for the federal state of North Rhine-Westphalia (NRW) in Germany.
View Article and Find Full Text PDFArticle Synopsis
- PSMA-PET, introduced in 2012, has significantly improved prostate cancer staging, leading to the development of the PROMISE criteria for standardized imaging reports.
- This study analyzed data from a large cohort of prostate cancer patients across multiple German hospitals to assess the prognostic value of PROMISE staging in comparison to existing clinical risk assessment models.
- The findings from 2,414 patients revealed that PPP staging had performance metrics comparable to established clinical risk scores, thus highlighting its potential usefulness in predicting overall survival outcomes.